Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Kholoud E. Ibrahim, Bachelor
- Phone Number: +20 01066645179
- Email: Khloud_elsayed@azhar.edu.eg
Study Contact Backup
- Name: Gellan A. Mohamed, Doctoral
- Phone Number: +20 01062602678
- Email: gelan.alaa@azhar.edu.eg
Study Locations
-
-
-
Cairo, Egypt
- National Hepatology and Tropical Medicine Research Institute
-
Contact:
- Amin M. Abdel Baki, Physician
- Phone Number: +02 01014502029
- Email: dr_amin114@yahoo.com
-
Principal Investigator:
- Amin M. Abdel Baki, Physician
-
Sub-Investigator:
- Kholoud E. Ibrahim, Pharmacist
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years and older.
- Grade I and II hepatic encephalopathy.
Exclusion Criteria:
- Pregnant and breastfeeding women.
- Grade III and IV hepatic encephalopathy.
- Individuals confirmed to be allergic to milk protein
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Lactoferrin bovine once a day
15 patients will be subjected to take 100mg of lactoferrin bovine in the form of sachets twice per day for 15 days.
|
Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
Other Names:
|
|
Active Comparator: Lactoferrin bovine twice a day
15 patients will be subjected to take 100mg of lactoferrin bovine in the form of sachets once per day for 15 days.
|
Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
Other Names:
|
|
No Intervention: Control group
15 patients will be subjected to take only the standard treatment regimen that is applied at the National hepatology and tropical medicine research institute in Egypt.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in serum concentration of inflammatory cytokines
Time Frame: 15 days
|
Change in serum concentration of inflammatory cytokine Tumor necrosis factor-alpha (TNF-a) (pg/ml)
|
15 days
|
|
Change in serum concentration of Nuclear factor kB
Time Frame: 15 days
|
Change in serum concentration of Nuclear factor kB (NFkB) (ng/ml)
|
15 days
|
|
Change in serum concentration of oxidative stress markers
Time Frame: 15 days
|
Change in serum concentration of oxidative stress markers Malondialdehyde (MDA) (n.mol/mg/protein) and Glutathione (GSH) (m.mol/mg/protein)
|
15 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Psychometric Hepatic Encephalopathy Score (PHES)
Time Frame: 15 days
|
Number connection test A (NCT-A) - in this test the numbers have to be joined consecutively in ascending numerical order (1, 2, 3…) as quickly as possible.
|
15 days
|
|
Change in Psychometric Hepatic Encephalopathy Score (PHES)
Time Frame: 15 days
|
Digit symbol test (DST) - in this test the patient is given a series of double-boxes with a number given in the upper part.
The task is to draw a symbol pertinent to this number into the lower part of the boxes.
Nine fixed pairs of numbers and symbols are given at the top of the test sheet.
Test result is the number of boxes correctly filled within 90 seconds.
|
15 days
|
|
Change in Psychometric Hepatic Encephalopathy Score (PHES)
Time Frame: 15 days
|
Simplified animal naming test (S-ANT) - in this test patients are asked to name as many animals as possible in one minute.
Repeats and errors were excluded from the calculation.
The number of named animals after one minute was the definitive score.
|
15 days
|
|
Length of hospital stay
Time Frame: 15 days
|
Length of hospital stay
|
15 days
|
|
The rate of adverse events occurring during the treatment
Time Frame: 15 days
|
Number of patients who experienced adverse events such as diarrhea, rash, loss of appetite, fatigue, and constipation.
|
15 days
|
|
Number of patients transferred to ICU
Time Frame: 15 days
|
Number of patients transferred to ICU
|
15 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Amin M. Abdel Baki, Doctoral, National Hepatology and Tropical Medicine Research Institute
- Study Director: Nayira A. Abdel Baky, Doctoral, Al-Azhar University
Publications and helpful links
General Publications
- Bajaj JS. Hepatic encephalopathy: classification and treatment. J Hepatol. 2018 Apr;68(4):838-839. doi: 10.1016/j.jhep.2017.11.005. No abstract available.
- Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2048-61. doi: 10.1016/j.cgh.2015.06.039. Epub 2015 Jul 9.
- Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):157-174. doi: 10.1016/j.cld.2020.01.001. Epub 2020 Mar 2.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Lactoferrin in HE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.